Platelet-rich plasma (PRP) · Lesson 25 of 25 · 3 min

What does evidence-based PRP practice look like?

A summary of how PRP evidence is tiered by condition, the barriers to wider adoption, and the habits that define careful, evidence-based practice.

Gloved hands placing a sample tube into a centrifuge

Key takeaways.

  • A 2024 review of 75 randomized trials (5,726 people) found wide variation in PRP preparation and use.
  • The course tiers evidence as strong, moderate or insufficient depending on the condition.
  • Leukocyte-rich and leukocyte-poor PRP are matched to different tissues in the research.
  • Barriers include limited insurance coverage, no standard protocols and little long-term data.
  • Tracking outcomes with validated patient-reported measures is part of good practice.
  • PRP applications are considered off-label, and consent must reflect that.

Evidence is tiered by condition

A 2024 systematic review analyzed 75 randomized controlled trials involving 5,726 people. It found significant variation in how PRP was prepared and applied. This variation is the field's main challenge.

The course sorts uses into tiers. It rates the evidence base strongest for knee osteoarthritis, lateral epicondylitis and androgenetic alopecia. It rates evidence as moderate for rotator cuff tendinopathy, plantar fasciitis, chronic wounds and female stress urinary incontinence.

Evidence is rated insufficient for Achilles tendinopathy, acute ACL augmentation and acute muscle injuries. In these, PRP has not shown superiority over controls.

Formulation matters

PRP is not one product. Leukocyte-rich PRP contains more white blood cells and leukocyte-poor PRP contains fewer. The research associates leukocyte-rich PRP with tendon conditions and leukocyte-poor PRP with osteoarthritis.

Dose is also under study. Meta-analyses from 2024 have examined how total platelet dose relates to outcomes.

Barriers to adoption

A 2024 analysis listed several barriers. Insurance coverage is limited and out-of-pocket costs are high. Protocols are not standardized, so outcomes vary between clinics.

Regulatory classification is described as ambiguous, and frameworks differ between countries. Most studies report outcomes at 3 to 12 months, so long-term durability is uncertain. PRP applications are considered off-label.

Habits of careful practice

Careful practice starts by checking that the condition has at least moderate supporting evidence. It then screens for contraindications using the 2025 GRIIP consensus.

Outcomes should be tracked with validated patient-reported outcome measures at set intervals. Consent should address therapeutic misconception, which is a patient's tendency to overestimate benefit from an investigational treatment. Ongoing education is needed because the evidence changes quickly.

Educational content for healthcare professionals. Not a treatment recommendation. PRP applications are considered off-label.

Platelet-rich plasma (PRP): 0 of 25 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • A step-by-step patient selection framework
  • Matching PRP formulation to the indication
  • Setting up outcome tracking in clinic
  • Consent and ethics in practice
  • Building a continuing education plan

Common questions.

Which PRP uses have the strongest evidence?
The course rates the evidence base strongest for knee osteoarthritis, lateral epicondylitis with leukocyte-rich PRP, and androgenetic alopecia. Evidence quality still varies, and PRP applications are considered off-label.
What is the difference between leukocyte-rich and leukocyte-poor PRP?
They differ in white blood cell content. Research associates leukocyte-rich PRP with tendon conditions and leukocyte-poor PRP with osteoarthritis.
Why is PRP not more widely adopted?
Reported barriers include limited insurance coverage, high out-of-pocket cost, a lack of standardized protocols, variable outcomes, equipment cost and limited long-term data.

Sources

  • Smith J, et al. Systematic review of platelet-rich plasma in medical and surgical specialties: quality, evaluation, evidence, and enforcement. Plast Reconstr Surg. 2024;154(2):402e-414e.
  • Li W, et al. An umbrella review of the use of platelet-rich plasma in the treatment of androgenetic alopecia. J Cosmet Dermatol. 2023;22(3):827-838.
  • Cole BJ, et al. The effect of platelet dose on outcomes after platelet rich plasma injections for musculoskeletal conditions: a systematic review and meta-analysis. Curr Rev Musculoskelet Med. 2024;17(5):234-247.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.